Ron Lanton III, Esq

Ron Lanton advises pharmacies to maintain compliance, explore contingency options, and stay engaged with policymakers during the government shutdown.

Implementing screening and testing services by pharmacists will expand access to care for patients.

Many industry stakeholders have been wrestling with difficult questions: How should the fair value of a drug be determined?

Cannabidiol (CBD) has certainly drawn significant attention over the past few months.

On February 6, 2019, the Department of Health and Human Services (HHS) proposed a rebate rule, Fraud and Abuse; Removal of Safe Harbor Protection for Rebates Involving Prescription Pharmaceuticals and Creation of New Safe Harbor Protection for Certain Point-of-Sale Reductions in Price on Prescription Pharmaceuticals and Certain Pharmacy Benefit Manager Service Fees.

One way that policymakers and industry insiders have constantly considered to lower drug prices has been through importation.

For a current compounder or someone looking to enter the space, it is imperative that their business remains on top of the latest compounding developments.

There have been several recent federal efforts aimed at bringing more balance into the market by increasing PBM oversight.

Genetic discrimination occurs when people are treated differently by their employer or insurance company because they have a genetic mutation that causes or increases the risk of an inherited disorder or they have a familial history of a specific health condition.

The final days of the Obama administration witnessed the federal government launch several initiatives seeking to advance the battle against cancer. 

While biosimilars have the potential to slow the dramatic rise in the overall drug spend, many questions need to be answered.

With the growth of fitness apps, electronic health records, and telemedicine, mobile health is poised to enter the specialty pharmacy space.

The biggest problem the United States health care system faces is preventable disease. We do not have enough doctors, nurses, or health coaches to fix it.

Changes in reimbursement or in how specialty drugs are prescribed will impact the bottom line of specialty pharmacies.

Although it remains to be seen which medications will be approved to treat Duchenne muscular dystrophy, lawmakers have tried to make the path easier.

Pharmacy stakeholders who work with electronic health care data need to be vigilant against security breaches.

Cost containment of medications for the treatment of cancer is an area of increasing concern for specialty pharmacy stakeholders.

As specialty medication costs rise, stakeholders seek to find a balance between cost containment and patient access.

As specialty medication costs rise, stakeholders seek to find a balance between cost containment and patient access.

A recent congressional spending bill prohibits federal agents from raiding retail medical cannabis operations in states that allow medical marijuana.